结肠癌患者术后医院感染的病原菌及耐药性检测研究

Pathogenic Bacterium Distribution and Drug-resistance Analysis on the Patients with Nosocomial Infection Following Surgery for Colorectal Carcinoma

为研究结肠癌患者术后医院感染的病原菌及耐药性检测结果,选择我院2015年5月至2018年5月结肠癌术后感染患者120例,使用全自动微生物分析仪对患者术后切口感染的标本组织进行细菌鉴定和药敏检测。分析其菌株分布特点、大肠埃希菌对抗菌药物的耐药率。结果显示,1)结肠癌术后感染患者120例中,革兰阳性菌56株(46.67%),包括26株表皮葡萄球菌、21株金黄色葡萄球菌、5株溶血葡萄球菌、其他4株;革兰阴性菌64株(53.33%),包括大肠埃希菌28株、肺炎克雷伯菌9株、铜绿假单胞菌8株、鲍氏不动杆菌8株、其他11株。2)大肠埃希菌属于一种常见的革兰阴性菌,在本次研究中,大肠埃希菌耐药率最高的抗菌药物为头孢唑林(100.00%),其次为磺胺甲恶唑/甲氧苄啶(89.29%)、红霉素(82.14%)、头孢曲松(82.14%)、庆大霉素(71.43%)、头孢噻肟(67.86%)、头孢他啶(53.57%)。结果表明,结肠癌手术患者术后感染病原菌类型较多,耐药性强,应当对耐药进行密切的监测,从而为抗菌药物的合理选择提供重要的指导依据。

This study was to investigate pathogenic bacterium distribution of nosocomial infection following surgery for colorectal carcinoma,and to analyse their drug-resistance,enrolled 120 cases of postoperative infection(2015-05-2018-05,in author's hospital)into this research,i.e,to collect specimen tissue from infected wound after operation,and to take bacterium appraisal and drug-sensitivity test,then based on the obtained results to analyse bacterium distribution charateristics,and the drug-resistant ratio of E.coli against antibacterial drugs.As results,1) among the 120cases,G+bacterium were in 56 strains(46.67%) including 26 strains of Staphylococcusepidermidie,21 strains of staphylococcusaureus,5strains of staphylococcus haemolyticus,4strains of other;G-bacterium were in 64strains(53.33%) including 28 strains of E.coli,9 strains of klebsiella pneumoniae,8 strains of pseudomons aeruginosa ,8 strains of boydii,11strains of other;2) E.coli is a common G-bacteria,in its most high drug-resistant rate's drugs cefazolin was the first(100%),the nexts were sulfamethoxazole trimethoprim (89.29%),erythrocin (82.14%),ceftriaxone(82.14%),gentamycine(71.43%),cefotaxime(67.86%) and ceftazidime(53.67%). Results show that postoperative infectious pathogenic types in colorectal carcinoma patients are various, and their drug-resistance are hight,thus it should be to closely monitor it in order to provide important guidance for the rational selection of anti-badterium drugs.